Welcome to our dedicated page for GLOBUS MEDICAL SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Globus Medical, Inc. reported preliminary unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025. At the same time, the company issued preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026, giving investors an early view of expected performance for the coming year. These updates were shared through a press release dated January 7, 2026, which is furnished as an exhibit to this report.
Globus Medical Inc. director reports equity gift
A director of Globus Medical Inc. reported a transaction in the company’s Class A common stock dated 01/02/2025 with transaction code "G", indicating a gift. The filing shows 6,100 shares of Class A common stock were disposed of at a stated price of $0 as part of this gift transaction.
Following the reported transaction, the director beneficially owns 510,175 shares of Class A common stock directly. In addition, 165,967 shares are held indirectly through the Davidar Family Irrevocable Trust U/A 8/6/09, which is a trust for the benefit of the reporting person’s spouse and children, with the spouse serving as trustee.
Globus Medical Inc. director reported selling 4,000 shares of Class A common stock on 12/12/2025 at $88.85 per share in a transaction carried out under a Rule 10b5-1 trading plan dated September 12, 2025.
Following this planned sale, the director directly owns 12,419 shares of Globus Medical stock, as disclosed in the Form 4 filing.
GMED has a notice of proposed insider share sales under Rule 144. The filer plans to sell 4,000 shares of GMED common stock through Raymond James & Associates on the NYSE, with an aggregate market value of $355,000. The filing lists 133,839,166 shares of this class outstanding.
The seller acquired 10,000 common shares on 09/01/2023 through restricted stock unit (RSU) vesting from the issuer, and the planned sale represents part of that amount. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about GMED’s current or future operations.
Globus Medical's executive chairman, who is also a director and 10% owner, reported exercising stock options for 34,375 shares of Class A common stock at $25.52 per share on 12/08/2025. Following this option exercise, he directly owns 60,417 shares of Globus Medical Class A common stock.
The derivative position was a stock option giving the right to buy 34,375 Class A shares at an exercise price of $25.52. These options were originally granted on January 25, 2016, are fully vested, and relate to 34,375 underlying Class A shares with an expiration date of 01/25/2026.
Globus Medical reported insider activity by its Senior Vice President and Chief Financial Officer. On December 1, 2025, the executive exercised multiple stock options for Class A common stock, acquiring 3,646 shares at $53.14, 5,000 shares at $56.43, 5,000 shares at $64.44, and 4,896 shares at $63.68. The same day, the executive sold 18,542 shares at $90 per share, leaving no directly held Class A common stock after the reported transactions.
The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025. The options exercised were previously granted awards that vest over four years or are already fully vested, with expiration dates ranging from 2031 to 2034.
Globus Medical Inc. insider activity: A senior vice president who also serves as general counsel and corporate secretary reported an options exercise and stock sale in Class A common stock. On 11/25/2025, the executive exercised stock options covering 7,500 shares at an exercise price of $25.96 per share, increasing direct ownership of common stock to 7,500 shares.
On the same date, the executive sold 7,500 shares of Class A common stock at $90 per share under a Rule 10b5-1 trading plan dated December 4, 2024. Following these transactions, the reporting person disclosed beneficial ownership of 0 shares of Class A common stock and 0 related stock options.
Globus Medical, Inc. (GMED) insider filed a Form 144 notice to sell 7,500 shares of common stock. The planned sale, to be executed through Raymond James & Associates on the NYSE, has an stated aggregate market value of $675,000. The filing notes that 133,839,166 shares of common stock are outstanding. The shares to be sold were acquired on 11/25/2025 via a cashless stock option exercise from the issuer, with payment also dated 11/25/2025 and described as a cashless exercise.
Globus Medical Inc. (GMED) director reported an insider transaction involving company Class A common stock. On 11/12/2025, the reporting person exercised 25,000 stock options at an exercise price of $25.52 per share and on the same date sold 25,000 shares of Class A common stock at a weighted average price of $86.0002 per share. After these transactions, the director directly beneficially owns 516,275 shares of Class A common stock and indirectly beneficially owns 165,967 shares held in a family trust. The reported options were granted on January 25, 2016 and are fully vested.
Globus Medical (GMED) reported an insider transaction by a director. On 11/11/2025, the director exercised stock options for 25,000 Class A shares at $44.14 and then sold 25,000 Class A shares at a $84.2903 weighted average price.
Following these transactions, the director held 0 shares directly. The options were granted on May 1, 2019, were fully vested, and had an expiration date of 05/01/2029.